Episode 454: Managing MS-Related Depression with Dr. Anthony Feinstein

One out of every two people with MS will experience clinical depression at some point in their MS journey, making depression one of the most significant yet under-discussed aspects of living with MS. While the physical symptoms of MS often take center stage, the neuropsychiatric challenges can be just as impactful on an individual's overall quality of life and long-term outcomes.

Joining us to shed some light on this important topic is Dr. Anthony Feinstein, a world-renowned neuropsychiatrist and professor at the University of Toronto. Dr. Feinstein has spent decades researching the biological and psychological drivers of depression in MS.

We're also sharing study results revealing that wait times to see a neurologist in the U.S. are way too long.

We'll tell you about a pilot trial that's recruiting participants for an implantable device designed to promote remyelination.

We're just two days away from the National MS Society's webcast on protecting federal funding for MS research, the NIH, CDC, and FDA. We're sharing all the details and info to register.

And we'll tell you all about the MS Society's statement for the record at a congressional hearing, exposing how Pharmacy Benefit Managers often prioritize profits over patient welfare.

We have a lot to talk about! Are you ready for RealTalk MS??!

This Week: Managing MS-Related Depression :22

Study results reveal wait times for an appointment with a neurologist in the U.S. 1:45

A pilot clinical trial for an implantable device designed to promote remyelination 4:38

A webcast to update you on the National MS Society's advocacy efforts to protect federal funding for MS research, the NIH, CDC, and FDA 7:05

The National MS Society has submitted a critical statement for the record at a congressional hearing, exposing how Pharmacy Benefit Managers often prioritize profits over patient welfare 8:39

Dr. Anthony Feinstein discusses the latest research and strategies for managing MS-related depression 11:00

Share this episode 29:37

Next week 28:56

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/454

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes at www.RealTalkMS.com

STUDY: Access to High-Efficacy Therapies for Multiple Sclerosis Under Medicaid: Variation in Coverage and Utilization Across States
https://aan.com/msa/Public/Events/AbstractDetails/61520

STUDY RESULTS: Neurology Wait Times After Primary Care or Emergency Department Visits Among the Commercially Insured Population in the United States: 2019-2023
https://www.neurology.org/doi/10.1212/WNL.0000000000218008

CLINICAL TRIAL: The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
https://clinicaltrials.gov/study/NCT06796504

WEBCAST: Make It Count Now: Mobilizing for Federal Funding in a Changing Policy Landscape
https://nmss.quorum.us/event/33151

READ: The National MS Society Statement for The Record: "Profits Over Patients: The PBM Business Model Under Scrutiny"
https://cdn.sanity.io/files/y936aps5/production/0372d3964cc269a404c17dff8ca919b34d0c6603.pdf

AbleNOW
https://ablenow.com

JOIN: The RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

REVIEW: Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on X, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Episode 454
Guest: Dr. Anthony Feinstein

Privacy Policy